GlassScriptPhysician profile
Ihor Susak
NPI 1598547481
$1,886.10
in general payments reported to CMS, 2019-2025
20 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $36.42 · 2024: $832 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $471.83 | 2023-2025 | Repatha, Repatha |
| Cvrx, INC. | $236.02 | 2024-2025 | Barostim Neo System |
| Stryker Corporation | $140.25 | 2025 | Limflow System |
| Astrazeneca Pharmaceuticals LP | $118.95 | 2024-2025 | Lokelma |
| Novartis Pharmaceuticals Corporation | $118.64 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.88 | 2024-2025 | Lifevest |
| Edwards Lifesciences Corporation | $105.48 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $103.51 | 2024 | Assurity |
| Merck Sharp & Dohme LLC | $97.33 | 2023-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.70 | 2024-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $58.21 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $56.45 | 2024 | Xarelto |
| Pfizer INC. | $40.45 | 2025 | |
| Scpharmaceuticals INC. | $27.80 | 2024 | |
| Philips North America LLC | $21.07 | 2024 | (Ck4) Mcot |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $20.63 | 2025 | |
| Glaxosmithkline, LLC. | $19.09 | 2025 | Shingrix, Arexvy |
| Bridgebio Pharma, INC. | $16.59 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $16.45 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.77 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ihor Susak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.